Oncopeptides AB (publ)

OM:ONCO BTA Stock Report

Market Cap: SEK 717.3m

Oncopeptides Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of ONCO BTA?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders4,613,0762.1%
VC/PE Firms16,401,9117.48%
Institutions25,229,38611.5%
General Public173,102,32378.9%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 132.6%.

Top Shareholders

Top 25 shareholders own 21.87% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
7.48%
Odlander, Fredrikson & Co. AB
16,401,911SEK 53.6m0%1.87%
3.78%
Industrifonden
8,286,806SEK 27.1m0%6.79%
3.34%
Redmile Group, LLC
7,319,861SEK 23.9m0%0.09%
1.36%
Avanza Fonder AB
2,982,165SEK 9.8m0%0.02%
1.03%
Handelsbanken Asset Management
2,268,252SEK 7.4m0%no data
0.96%
SEB Investment Management AB
2,105,589SEK 6.9m0%no data
0.81%
Swedbank Robur Fonder AB
1,780,262SEK 5.8m0%no data
0.47%
A. Clipper
1,039,239SEK 3.4m0%no data
0.4%
Jakob Lindberg
868,331SEK 2.8m0%no data
0.3%
Harri Salminen
668,728SEK 2.2m0%no data
0.26%
Adrigo Asset Management AB
569,322SEK 1.9m0%0.31%
0.19%
Kjell Hasslert
415,695SEK 1.4m0%no data
0.19%
Swedbank Försäkring AB, Asset Management Arm
415,695SEK 1.4m0%0.29%
0.18%
Per Wold-Olsen
389,385SEK 1.3m0%no data
0.18%
State Street Global Advisors, Inc.
388,585SEK 1.3m0%no data
0.16%
Futur Pension Försäkringsaktiebolag, Asset Management Arm
352,437SEK 1.2m0%0.03%
0.15%
Alan Hulme
325,327SEK 1.1m0%no data
0.14%
Linfan Zhang
307,253SEK 1.0m0%no data
0.13%
Hans Ohman
289,179SEK 945.6k0%no data
0.1%
Storebrand Fonder AB,
225,788SEK 738.4k0%no data
0.1%
FCG Fonder AB
220,458SEK 720.9k0%0.02%
0.055%
Eva Nordström
120,200SEK 393.1k0%no data
0.046%
Klaas Bakker
100,000SEK 327.0k0%no data
0.029%
Tcax Förvaltning Ab
63,720SEK 208.4k0%no data
0.026%
Jarl Jungnelius
57,750SEK 188.9k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/05/15 23:58
End of Day Share Price 2024/05/13 00:00
Earnings2023/12/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Oncopeptides AB (publ) is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Erik HultgårdCarnegie Investment Bank AB
Patrik LingDNB Markets
Robert BurnsH.C. Wainwright & Co.